Literature DB >> 20510833

Pancreatic enzyme replacement therapy in chronic pancreatitis.

E C M Sikkens1, D L Cahen, E J Kuipers, M J Bruno.   

Abstract

Exocrine pancreatic insufficiency (EPI) is a serious condition which occurs in several diseases including chronic pancreatitis (CP), cystic fibrosis, pancreatic cancer, and as a result of pancreatic surgery. The lack or absence of pancreatic enzymes leads to an inadequate absorption of fat, proteins, and carbohydrates, causing steatorrhoea and creathorrhea which results in abdominal discomfort, weight loss, and nutritional deficiencies. To avoid malnutrition related morbidity and mortality, it is pivotal to commence pancreatic enzyme replacement therapy (PERT) as soon as EPI is diagnosed. Factors as early acidic inactivation of ingested enzymes, under dosage, and patient incompliance may prevent normalisation of nutrient absorption, in particular of fat digestion. This review focuses on the current status of how to diagnose and treat EPI. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20510833     DOI: 10.1016/j.bpg.2010.03.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  25 in total

Review 1.  Pancreatic Exocrine Insufficiency as a Complication of Gastrointestinal Surgery and the Impact of Pancreatic Enzyme Replacement Therapy.

Authors:  Adarsh Chaudhary; J Enrique Domínguez-Muñoz; Peter Layer; Markus M Lerch
Journal:  Dig Dis       Date:  2019-08-16       Impact factor: 2.404

Review 2.  [Exocrine pancreatic insufficiency and diabetes mellitus].

Authors:  Raimund Weitgasser; Heidemarie Abrahamian; Martin Clodi; Sandra Zlamal-Fortunat; Heinz F Hammer
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

3.  Pancrelipase delayed-release capsules for the treatment of pancreatic insufficiency.

Authors:  David C Whitcomb
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-04

4.  Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment.

Authors:  C J Tuck; K M Taylor; P R Gibson; J S Barrett; J G Muir
Journal:  Am J Gastroenterol       Date:  2017-08-15       Impact factor: 10.864

5.  Proteomic analysis (GeLC-MS/MS) of ePFT-collected pancreatic fluid in chronic pancreatitis.

Authors:  Joao A Paulo; Vivek Kadiyala; Linda S Lee; Peter A Banks; Darwin L Conwell; Hanno Steen
Journal:  J Proteome Res       Date:  2012-02-07       Impact factor: 4.466

Review 6.  Applications of stable isotopes in clinical pharmacology.

Authors:  Reinout C A Schellekens; Frans Stellaard; Herman J Woerdenbag; Henderik W Frijlink; Jos G W Kosterink
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

Review 7.  Pharmacological challenges in chronic pancreatitis.

Authors:  Anne Estrup Olesen; Anne Brokjaer; Iben Wendelboe Fisher; Isabelle Myriam Larsen
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

8.  [Position paper: Exocrine pancreatic insufficiency and diabetes mellitus].

Authors:  Raimund Weitgasser; Heidemarie Abrahamian; Martin Clodi; Werner Fortunat; Heinz Hammer
Journal:  Wien Klin Wochenschr       Date:  2012-12       Impact factor: 1.704

Review 9.  TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.

Authors:  M Benavides; A Abad; I Ales; A Carrato; E Díaz Rubio; J Gallego; J García-Foncillas; C Grávalos; B Laquente; C Pericay; F Rivera; J Tabernero; E Aranda
Journal:  Clin Transl Oncol       Date:  2014-04-12       Impact factor: 3.405

Review 10.  Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century.

Authors:  Tony Trang; Johanna Chan; David Y Graham
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.